Utilizing combination therapy in the treatment of Alzheimer’s disease

References

• Evans DA, Funkenstein HH, Albert MS et al Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAIVIA 262(18), 2551–2556 (1989).
   PubMed Web of Science ®Google Scholar
• Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer's disease in the US population: prevalence estimates using the 2000 census. Arch. Neural. 60(8), 1119–1122 (2003).
   Google Scholar
• Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health 88(9), 1337–1342 (1998).
   Google Scholar
• Hebert LE, Beckett LA, Scherr PA, Evans DA. Annual incidence of Alzheimer's disease in the United States projected to the years 2000 through 2050. Alzheimer Dis. Assoc. Disarl 15(4), 169–173 (2001).
   Google Scholar
• Bartus RT, Dean RL III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 217(4558), 408–414 (1982). Excellent evidence-based description of the cholinergic hypothesis of Alzheimer's disease (AD).
   Google Scholar
• Raskind MA, Peskind ER, Wessel T, Yuan W Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology54(12), 2261–2268 (2000).
   Google Scholar
• Tariot PN, Solomon PR, Morris JC et al A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology54(12), 2269–2276 (2000).
   Google Scholar
• Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. Br Merl 321(7274), 1445–1449 (2000).
   Google Scholar
• Rosler M, Anand R, Cicin-Sain A et al Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BE Merl 318(7184), 633–638 (1999).
   Google Scholar
• Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. kit. J. Geriatric PTchopharmacol 1,55–65 (1998).
   Google Scholar
• Schneider LS, Anand R, Farlow MR. Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease. Int. J. Geriatric Bychophalmacol l(Suppl. 1), S26—S34 (1998).
   Google Scholar
• Rogers SL, Doody RS, Mohs RC, Friedhoff LT Donepezil improves cognition and global function in Alzheimer's disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Awl?. Intern. Merl 158(9), 1021–1031 (1998).
   Google Scholar
• Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology50(1), 136–145 (1998).
   Google Scholar
• Potkin SG. The ABC of Alzheimer's disease: ADL and improving day-to-day functioning of patients. int. Rychogeriah: 14\(Suppl. 1), 7–26 (2002).
   Google Scholar
• Wynn ZJ, Cummings JL. Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease. Dement. Geriatr Cogn. Bisonl. 17(1–2), 100–108 (2004).
   Google Scholar
• Geldmacher DS. Alzheimer's disease: current pharmacotherapy in the context of patient and family needs. J. Am. Geriatr Soc. 51(5 Suppl. Dementia), S289—S295 (2003).
   Google Scholar
• Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch. Neural. 61(2), 252–256 (2004).
   Google Scholar
• Finucane TE. Another advertisement for donepezil. jAm. Geriatr Soc. 52(5), 843 (2004).
   PubMed Web of Science ®Google Scholar
• Karlawish JH. Donepezil delay to nursing home placement study is flawed. J. Am. Geriatr Soc. 52(5), 845 (2004).
   Google Scholar
• Royall. DR. Donepezil's effects remain uncertain. jAm. Geriati: Soc. 52 (5), 843–844 (2004).
   PubMed Web of Science ®Google Scholar
• Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD. Open-label, multicenter, Phase III extension study of the safety and efficacy of donepezil in patients with Alzheimer's disease. Atrh. Neural. 58(3), 427–433 (2001).
   Google Scholar
• Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur. Neumpsychophalmacol 10(3), 195–203 (2000).
   PubMed Web of Science ®Google Scholar
• Greenamyre JT, Maragos WF, Albin RL, Penney JB, Young AB. Glutamate transmission and toxicity in Alzheimer's disease. Prog. Neuropsychopharmacol Biol. Psychiatry 12 (4), 421–430 (1988). Landmark report of the role of excitotoxicity in AD.
   Google Scholar
• Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Phatmacol Ther 81(3), 163–221 (1999).
   Google Scholar
• Olney JW, Wozniak DF, Farber NB Excitotoxic neurodegeneration in Alzheimer's disease. New hypothesis and new therapeutic strategies. Arch. Neural 54(10), 1234–1240 (1997).
   Google Scholar
• Potkin S, Peskin ER, Pomara N et al. Memantine monotherapy is effective and safe for the treatment of mild-to-moderate Alzheimer's disease: a randomized controlled trial. 56th Annual Meeting- of the American Academy of Neurology CA, USA (2004).
   Google Scholar
• Winblad B, Poritis N. Memantine in severe dementia: results of the M-BEST Study (benefit and efficacy in severely demented patients during treatment with memantine). Int. J. Ceriatr Psychiatry 14(2), 135–146 (1999).
   Google Scholar
• Reisberg B, Doody R, Stoffler A et al Memantine in moderate-to-severe Alzheimer's disease. N Engl. J. Med. 348(14), 1333–1341 (2003).
   Google Scholar
• Reisberg B, MObius H-J, Schmitt F, Doody R. Long-term efficacy and safety benefits from treatment with the NMDA antagonist memantine: results of a 24-week, open-label extension study in moderate-to-severe Alzheimer's disease. Eur. Neuropsychopharmacol 13\(Suppl. 4), S388 (2003).
   Google Scholar
• Rutten BP, Steinbusch HW, Korr H, Schmitz C. Antioxidants and Alzheimer's disease: from bench to bedside (and back again). Curi: Opin. Gun. Nub: Metab. Cate 5(6), 645–651 (2002).
   Google Scholar
• Christen Y. Oxidative stress and Alzheimer's disease. Ainj Gun. Nub: 71 (2), S621—S629 (2000).
   Google Scholar
• Pratico D, Delanty N. Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. Am. J. Med. 109 (7), 577–585 (2000).
   Google Scholar
• Zandi PP, Anthony JC, Khachaturian AS et al Reduced risk of Alzheimer's disease in users of antioxidant vitamin supplements: the Cache County Study. Arch. Neural. 61(1), 82–88 (2004).
   PubMed Web of Science ®Google Scholar
• Morris MC, Evans DA, Bienias JL et al. Dietary intake of anti-oxidant nutrients and the risk of incident of Alzheimer's disease in a biracial community study. JAIVIA 287(24), 3230–3237 (2002).
   PubMed Web of Science ®Google Scholar
• Engelhart MJ, Geerlings MI, Ruitenberg A et al Dietary intake of antioxidants and risk of Alzheimer's disease. JAMA 287(24), 3223–3229 (2002).
   PubMed Web of Science ®Google Scholar
• Sano M, Ernesto C, Thomas RG et al A controlled trial of selegiline, a-tocopherol, or both as treatment for Alzheimer's Disease. The Alzheimer's disease Co-operative Study. N Engl. J. Med. 336 (17), 1216–1222 (1997).
   Google Scholar
• •Pivotal study that demonstrated a lack of benefit of combination of selegiline and vitamin E over monotherapy.
   Google Scholar
• Cummings JL, Cole G. Alzheimer's disease. JAIVIA 287(18), 2335–2338 (2002).
   PubMed Web of Science ®Google Scholar
• Doody RS, Stevens JC, Beck C et al Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56 (9), 1154–1166 (2001).
   PubMed Web of Science ®Google Scholar
• •Evidence-based review, albeit slightly out of date, which concludes that despite modest benefits, cholinesterase inhibitors (ChM) should be considered standard of care for AD treatment, and vitamin E should be considered as adjunctive treatment.
   Google Scholar
• Tabet N, Feldmand H. Ibuprofen for Alzheimer's disease. Cochrane Database Syst Rev(2), CD004031 (2003).
   Google Scholar
• Laurin D, Masaki IKH, Foley DJ, White LR, Launer U. Midlife dietary intake of antioxidants and risk of late-life incident dementia: the Honolulu—Asia Aging Study. Am. Epidernial 159(10), 959–967 (2004).
   Google Scholar
• Luchsinger JA, Tang MX, Shea S, Mayeux R. Antioxidant vitamin intake and risk of Alzheimer's disease. Arch. Neural 60(2), 203–208 (2003).
   PubMedGoogle Scholar
• Zandi PP, Breitner JC. Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence. Neumbial Aging 22(6), 811–817 (2001).
   PubMed Web of Science ®Google Scholar
• McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Rev 21(2), 195–218 (1995).
   Google Scholar
• Akiyama H, Barger S, Barnum S et al Inflammation and Alzheimer's disease. Neurobial Aging21(3), 383–421 (2000).
   PubMed Web of Science ®Google Scholar
• Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenadmisoprostol in Alzheimer's disease. Neurology53(1), 197–201 (1999).
   PubMed Web of Science ®Google Scholar
• Sainati SM, Talwalker S. Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease. Stockholm—Springfield Symposium on Alzheimer Therapy Stockholm, Sweden (2002).
   Google Scholar
• Aisen PS. Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease. J. Pain Symptom Manage. 23\(Suppl. 4), S35—S40 (2002).
   Google Scholar
• Block G, Norman B, Liu G, Lines C, Reines S. A clinical trial of rofecoxib, a selective COX-2 inhibitor, for the treatment of Alzheimer's disease. Neurobiol Aging23, S1—S606 (2002).
   Google Scholar
• Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neumlogy 48(3), 626–632 (1997).
   PubMed Web of Science ®Google Scholar
• McGeer PL, McGeer EG. Anti- inflammatory drugs in the fight against Alzheimer's disease. Ann. N Y Acad. Sci. 777,213–220 (1996).
   PubMed Web of Science ®Google Scholar
• t' Veld BA, Ruitenberg A, Hofman A et al Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N Engl. J. Med. 345(21), 1515–1521 (2001).
   Google Scholar
• Etminan M, Gill S, Samii A. Effect of nonsteroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BE Med 327(7407), 128 (2003).
   PubMed Web of Science ®Google Scholar
• Baldereschi M, Di Carlo A, Lepore V et al Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging. Neumlogy 50(4), 996–1002 (1998).
   PubMed Web of Science ®Google Scholar
• Tang MX, Jacobs D, Stern Y et al Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 348(9025), 429–432 (1996).
   PubMed Web of Science ®Google Scholar
• Mulnard RA, Cotman CW, Kawas C et al Estrogen replacement therapy for treatment of mild-to-moderate Alzheimer's disease: a randomized controlled trial. Alzheimer's disease Co-operative Study. JAMA 283(8), 1007–1015 (2000).
   PubMed Web of Science ®Google Scholar
• Wassertheil-Smoller S, Hendrix SL, Limacher M et al Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JA/V/A 289 (20), 2673–2684 (2003).
   Google Scholar
• Shumaker SA, Legault C, Thal L et al Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JA1VIA 289(20), 2651–2662 (2003).
   Google Scholar
• Shumaker SA, Legault C, Kuller L et al Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study. JAIVIA 291(24), 2947–2958 (2004).
   PubMed Web of Science ®Google Scholar
• Espeland MA, Rapp SR, Shumaker SA et al Conjugated equine estrogens and global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study. JAIVIA 291(24), 2959–2968 (2004).
   PubMed Web of Science ®Google Scholar
• Birks J, Grimley EV, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst. Rev 4, CD003120 (2002).
   Google Scholar
• Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 356 (9242), 1627–1631 (2000).
   PubMed Web of Science ®Google Scholar
• Wolozin B, Kellman W Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer's disease associated with 3–
   Google Scholar
• •• hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neural. 57(10), 1439–1443 (2000).
   Google Scholar
• Tariot PN, Farlow MR, Grossberg GT et al. Memantine treatment in patients with moderate-to-severe Alzheimer's disease already receiving donepezil: a randomized controlled trial. JAIVIA 291(3), 317–324 (2004).
   PubMed Web of Science ®Google Scholar
• •Key trial demonstrating benefit of memantine in moderate—severe AD patients stabilized on donepezil.
   Google Scholar
• Klatte ET, Scharre DW, Nagaraja HN, Davis RA, Beversdorf DQ. Combination therapy of donepezil and vitamin E in Alzheimer's disease. Alzheimer Dis. Assoc. Disord. 17(2), 113–116 (2003).
   Google Scholar
• •Retrospective chart review demonstrating that donepezil and vitamin E in combination is more effective than placebo in slowing cognitive decline.
   Google Scholar
• Sobow T, Kloszewska I, Karlinska I. Addition of vitamin E to donepezil as a treatment for Alzheimer's disease. Alzheimer Rep. 2(3), 143–146 (1999).
   Google Scholar
• Schneider LS, Olin JT, Pawluczyk S. A double-blind crossover pilot study of 1-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease. Am. Psychiatry150(2), 321–323 (1993).
   Google Scholar
• Birks J, Flicker L. Selegiline for Alzheimer's disease. Cochrane Database Syst. Rev.(1), CD000442 (2003).
   Google Scholar
• Mann DB, Bierer LM, Lawlor BA et al L- deprenyl and physostigmine for the treatment of Alzheimer's disease. Psychiatry Res. 58(3), 181–189 (1995).
   Google Scholar
• Wilcock GK, Birks J, Whitehead A, Evans SJ. The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials. int. j Ceriatr fiychiatry 17 (2), 175–183 (2002) .
   PubMed Web of Science ®Google Scholar
• Schneider LS, Farlow MR, Henderson VW Pogoda JM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology 46(6), 1580–1584 (1996).
   PubMed Web of Science ®Google Scholar
• •Multicenter trial demonstrating that estrogen therapy enhances clinical response to tacrine.
   Google Scholar
• Rigaud AS, Andre G, Vellas B, Touchon J, Pere JJ. No additional benefit of HRT on response to rivastigmine in menopausal women with AD. Neurology60(1), 148–149 (2003).
   PubMed Web of Science ®Google Scholar
• Wenk GL, Quack G, Moebius HJ, Danysz W No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci. 66(12), 1079–1083 (2000).
   Google Scholar
• Periclou A, Ventura D, Sherman T, Rao N, Abramowitz W A pharmacokinetic study of the NMDA receptor antagonist memantine and donepezil in healthy young subjects.j Am Ceriatr Soc. 51 (S4), S225 (2003).
   Google Scholar
• Hartmann S, Mobius HJ. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int. Gun. Bychopharmacol 18(2), 81–85 (2003).
   Google Scholar
• ••Postmarketing safety report detailing thetolerability of memantine in combination with ChEls.
   Google Scholar
• Buckalew LW, Buckalew NM. Survey of the nature and prevalence of patients' noncompliance and implications for intervention. fiychol. Rep. 76 (1), 315–321 (1995).
   PubMed Web of Science ®Google Scholar
• Feldman H, Gauthier S, Hecker J et al A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology57 (4), 613–620 (2001).
   Google Scholar
• Blesa R, Davidson M, Kurz A et al Galantamine provides sustained benefits in patients with advanced moderate Alzheimer's disease for at least 12 months. Dement. Ceriatr Cogn. Disord. 15(2), 79–87 (2003).
   Google Scholar
• Wilkinson DG, Hock C, Farlow M, van Baelen B, Schwalen S. Galantamine provides broad benefits in patients with 'advanced moderate' Alzheimer's disease (MMSE 12) for up to 6 months. Int. J. Gun. Pract. 56(7), 509–514 (2002).
   Google Scholar
• Doraiswamy PM, Krishnan KR, Anand R et al Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits? Pmg. Neuropsychopharmacol Biol. Psychiatry26(4), 705–712 (2002).
   Google Scholar